摘要:
This invention is directed to novel compounds of Formula (I): ##STR1## wherein R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof and pharmaceutical compositions formulated therewith. This invention is also directed to a method for treating helminthiasis and for inhibiting reverse transcriptase activity in an animal by the administration of compounds of Formula (I).
摘要:
The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.
摘要:
Novel hypoglycemically active eremophilanolide sesquiterpenes which can be isolated from Psacalium spp., processes for obtaining the novel eremophilanolide sesquiterpenes and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes are described. Further described is the use of epicacalone, cacalone, cacalol or dimaturin as hypoglycemic agents, for example, in the treatment of diabetes. In a preferred embodiment, the hypoglycemically active compounds are obtained from the roots of Psacalium decompositum. As agents for the treatment of diabetes, the hypoglycemically active compounds of the present inventions are useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.
摘要:
The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as a dietary supplement to mammals suffering from elevated triglyceride levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypotriglyceridemic agents.
摘要:
The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.
摘要:
A novel hypoglycemically active triterpenoid compound isolated in purified, preferably substantially purified, form from Salacia spp., processes for obtaining the novel triterpenoid compound, compositions comprising the triterpenoid compound and methods for use a hypoglycemic agent, for example, in the treatment of diabetes, are described. In a preferred embodiment, the triterpenoid compound is obtained from Salacia prinoides. As an agent for the treatment of diabetes, the novel triterpenoid is useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.